Start Your Search
Poster Display Session (ID 63)
- Event: ELCC 2017
- Type: Poster Display Session
- Presentations: 1
- Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
127P - Prognostic significance of advanced lung cancer inflammation index (ALI) In untreated and treated stage IV non-small cell lung cancer (NSCLC): An Australian cancer centre experience (ID 172)
12:30 - 13:00 | Author(s): C. Oldmeadow
The role of advanced lung cancer inflammation index (ALI) at diagnosis is increasingly explored as an independent prognostic factor of survival in stage IV NSCLC. Post-treatment changes in ALI and the potential impact on survival are not clear in this group of patients. We aimed to evaluate prognostic role of ALI in stage IV NSCLC at diagnosis as well as post treatment.
A retrospective descriptive study was conducted for patients with stage IV NSCLC actively treated at Calvary Mater Newcastle, Australia from 2010 to 2015. Advanced lung cancer inflammation index (ALI = BMI x Albumin/NLR; BMI=Body mass index, NLR=Neutrophil-to-lymphocyte ratio, Albumin=Serum albumin g/dl) values calculated at diagnosis and post first cycle chemotherapy/targeted treatment. Demographic variables summarised and estimates of Kaplan-Meier (KM) survival distribution for overall survival (OS) generated. Extended Cox regression used to derive OS hazard ratios of predictive variables. Project approved by Research Ethics Committee.
A total of 279 patients with Stage IV NSCLC were treated during the study time. Baseline ALI was available for 276 patients and post first treatment cycle for 189 patients. The Cox PH model suggested ALI was a prognostic factor for OS, hazard ratio = 0.982 (95% CI: 0.973-0.991). Post first-cycle treatment, individuals with mean baseline ALI, had a hazard ratio = 0.391 (95% CI: 0.211-0.629) that was also increasing multiplicatively as a function of baseline ALI. At baseline, KM estimate suggested median survival was 6.23 months (95% CI: 4.83-9.27) for patients with ALI < 18 compared to 14.70 months (95% CI: 11.63-18.20) for those with ALI > 18. Post first-cycle treatment, not adjusted for baseline, patients with ALI < 18 median survival was 5.23 months (95% CI: 3.27-9.07) compared to 12.67 months (95% CI: 10.47-15.13) for ALI > 18.
ALI has a strong association with survival from baseline and post first-cycle treatment adjusted for baseline ALI. High pretreatment and post treatment ALI predicts for a longer survival while low pretreatment and post treatment ALI predicts for a shorter survival.
Clinical trial identification:
Legal entity responsible for the study:
Hunter New England Human Research Ethics Committee
Department of Medical Oncology, Calvary Mater Newcastle, Australia Hunter Medical Research Institute, Australia
All authors have declared no conflicts of interest.